PRESS RELEASE published on 11/14/2023 at 12:45, 2 years ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 1 month ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 1 month ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 3 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 2 years 4 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 2 years 4 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 2 years 5 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 2 years 6 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 2 years 6 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 2 years 7 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Published on 12/05/2025 at 02:35, 8 hours 27 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 10 hours 2 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 57 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 2 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:30, 32 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 47 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 22 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 32 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 57 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 2 hours 17 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 2 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 17 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 18 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
